Benjamin Edwards Inc. Has $1.13 Million Holdings in Medpace Holdings, Inc. $MEDP

Benjamin Edwards Inc. grew its position in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) by 81.3% in the 3rd quarter, HoldingsChannel reports. The fund owned 2,188 shares of the company’s stock after buying an additional 981 shares during the period. Benjamin Edwards Inc.’s holdings in Medpace were worth $1,125,000 as of its most recent SEC filing.

A number of other large investors also recently modified their holdings of the company. Clarkston Capital Partners LLC bought a new position in shares of Medpace during the second quarter valued at about $40,569,000. Brighton Jones LLC lifted its position in shares of Medpace by 160.4% during the 3rd quarter. Brighton Jones LLC now owns 4,060 shares of the company’s stock worth $2,087,000 after buying an additional 2,501 shares in the last quarter. Annex Advisory Services LLC lifted its position in shares of Medpace by 6.6% during the 3rd quarter. Annex Advisory Services LLC now owns 101,685 shares of the company’s stock worth $52,282,000 after buying an additional 6,264 shares in the last quarter. Jump Financial LLC purchased a new position in shares of Medpace in the 2nd quarter worth approximately $15,729,000. Finally, Arkadios Wealth Advisors bought a new position in shares of Medpace in the second quarter valued at approximately $327,000. 77.98% of the stock is currently owned by institutional investors.

Medpace Stock Up 0.7%

NASDAQ MEDP opened at $599.21 on Tuesday. The firm has a market cap of $16.88 billion, a P/E ratio of 41.90, a price-to-earnings-growth ratio of 2.00 and a beta of 1.43. The company’s 50 day moving average is $581.15 and its 200-day moving average is $504.33. Medpace Holdings, Inc. has a 12-month low of $250.05 and a 12-month high of $626.26.

Medpace (NASDAQ:MEDP) last released its quarterly earnings data on Wednesday, October 22nd. The company reported $3.86 earnings per share for the quarter, beating analysts’ consensus estimates of $3.50 by $0.36. The business had revenue of $659.90 million during the quarter, compared to analyst estimates of $640.49 million. Medpace had a net margin of 18.36% and a return on equity of 91.88%. Medpace’s revenue was up 23.7% compared to the same quarter last year. During the same period in the previous year, the business earned $3.01 EPS. Medpace has set its FY 2025 guidance at 14.600-14.860 EPS. Equities analysts expect that Medpace Holdings, Inc. will post 12.29 EPS for the current year.

Insider Buying and Selling

In other news, VP Susan E. Burwig sold 20,000 shares of the company’s stock in a transaction dated Monday, November 24th. The stock was sold at an average price of $609.15, for a total transaction of $12,183,000.00. Following the sale, the vice president directly owned 27,500 shares in the company, valued at $16,751,625. This represents a 42.11% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. Also, CFO Kevin M. Brady sold 3,000 shares of the firm’s stock in a transaction that occurred on Friday, November 21st. The shares were sold at an average price of $590.35, for a total transaction of $1,771,050.00. Following the completion of the transaction, the chief financial officer owned 6,000 shares of the company’s stock, valued at $3,542,100. This trade represents a 33.33% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last quarter, insiders have sold 387,925 shares of company stock valued at $233,386,647. Corporate insiders own 20.30% of the company’s stock.

Analyst Upgrades and Downgrades

MEDP has been the topic of several research analyst reports. TD Cowen boosted their price objective on Medpace from $356.00 to $462.00 and gave the stock a “sell” rating in a research report on Friday, October 24th. Mizuho set a $660.00 price target on shares of Medpace in a report on Friday. Truist Financial set a $555.00 price objective on shares of Medpace in a research report on Monday, October 27th. Weiss Ratings reissued a “buy (b)” rating on shares of Medpace in a research report on Friday, October 31st. Finally, BMO Capital Markets started coverage on shares of Medpace in a research note on Thursday, November 13th. They set a “market perform” rating and a $600.00 price target for the company. One analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, ten have assigned a Hold rating and four have given a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $491.27.

Medpace Company Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.